Cyndeo Wealth Partners LLC Sells 11,000 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT

Cyndeo Wealth Partners LLC decreased its holdings in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 43.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,250 shares of the company’s stock after selling 11,000 shares during the quarter. Cyndeo Wealth Partners LLC’s holdings in Eyepoint Pharmaceuticals were worth $134,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Adage Capital Partners GP L.L.C. grew its stake in shares of Eyepoint Pharmaceuticals by 7.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 6,200,000 shares of the company’s stock valued at $33,604,000 after buying an additional 450,000 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of Eyepoint Pharmaceuticals by 10.2% during the first quarter. Federated Hermes Inc. now owns 4,085,580 shares of the company’s stock valued at $22,144,000 after buying an additional 378,135 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Eyepoint Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company’s stock valued at $20,782,000 after buying an additional 31,141 shares during the last quarter. Hsbc Holdings PLC grew its stake in shares of Eyepoint Pharmaceuticals by 142.7% during the first quarter. Hsbc Holdings PLC now owns 625,140 shares of the company’s stock valued at $3,387,000 after buying an additional 367,525 shares during the last quarter. Finally, Deutsche Bank AG boosted its holdings in shares of Eyepoint Pharmaceuticals by 67.5% in the first quarter. Deutsche Bank AG now owns 357,442 shares of the company’s stock valued at $1,937,000 after purchasing an additional 144,060 shares during the period. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Stock Down 2.9%

Eyepoint Pharmaceuticals stock opened at $13.57 on Friday. The business has a fifty day moving average of $12.47 and a two-hundred day moving average of $9.31. The firm has a market cap of $935.34 million, a P/E ratio of -5.06 and a beta of 1.95. Eyepoint Pharmaceuticals, Inc. has a twelve month low of $3.91 and a twelve month high of $14.91.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%.The company had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $6.82 million. Equities analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on EYPT. HC Wainwright increased their price objective on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Royal Bank Of Canada initiated coverage on Eyepoint Pharmaceuticals in a report on Tuesday, June 17th. They issued an “outperform” rating and a $28.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Wednesday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $26.86.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.